QSP Model of modRNA to Treat Crigler-Najjar Syndrome Type 1

Collaboration with Alexion Pharmaceuticals - Published in CPT: Pharmacometrics & Systems Pharmacology

De-Risking Drug Discovery with Applied BioMath Assess™ An Early Feasibility Assessment Tool for Biotherapeutics

The steep cost of developing a new therapeutic to market. Early feasibility assessment (EFA) has proven to drastically improve the efficiency of pharmaceutical R&D and should be integrated into every drug R&D program. Applied BioMath Assess*, a new web-based application that provides the necessary models and analyses via an intuitive interface, makes this integration a reality.
*Patent pending